AstraZeneca shares drop 7% after report on $400 billion merger talks with Bristol Myers Squibb
--------------------------------------------------------------------
Source: CNBC
Published: 2026-08-03 17:17 UTC+10:00
Section: General
Factuality Score: 92
Opinion Category: Neutral
Topics: Business & Economy
--------------------------------------------------------------------
Snippet:
AstraZeneca shares dropped as much as 7% after a report that the U.K.'s largest drugmaker was in talks with U.S. peer Bristol Myers Squibb over a megadeal that, if completed, could value the companies at roughly $400 billion.
--------------------------------------------------------------------